ELCC 2021 Highlights
Podcast | English | 2021 | 26 Min
Image For Activity Cover
No Credit Offered
This edition of Lung Cancer Considered discusses important science presented at the recently completed European Lung Cancer Congress, the multidisciplinary lung cancer meeting co-organized by ESMO and IASLC. Dr. Enriqueta Felip and Dr. Fabrice Barlesi share their interpretation of the following clinical trials presented at ELCC:

Adagrasib (MRTX849) -- phase Ib expansion and phase II monotherapy cohorts
CheckMate 9LA -- randomized 719 patients with EGFR/ALK wild type NSCLC to standard chemotherapy or 2 cycles of chemotherapy with nivolumab and Ipilimumab
KEYNOTE-407-- randomized squamous NSCLC to carboplatin with choice of nab/ paclitaxel or paclitaxel, and either pembrolizumab or placebo
AMG 757-- BiTE: bispecific T-cell engager targeting DLL3 and engaging CD3
CAMEL-sq trial-- phase III randomized trial in patients with advanced squamous NSCLC
Dr. Enriqueta Felip
Dr. Fabrice Barles
Powered By